KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis.

Taha Ibrahim, Muhammad Burhan, Muhammad Abdullah Naveed, Ahila Ali, Zain Ul Abideen Shahid, Faiqah Nizam, Jawaria Ibrahim

J Antimicrob Chemother 81(2) dkaf469

PMID41549666
PMCID-
DOI10.1093/jac/dkaf469
发表日期2026-01-19
摘要

摘要

BACKGROUND: Antimicrobial resistance threatens oral treatment options for acute uncomplicated urinary tract infection (uUTI). Gepotidacin (Blujepa) is a novel oral triazaacenaphthylene antibiotic evaluated in Phase 3 trials versus nitrofurantoin. OBJECTIVES: To pool Phase 3 randomized evidence comparing gepotidacin and nitrofurantoin for efficacy and safety in female uUTI. METHODS: PRISMA-compliant systematic review and random-effects meta-analysis of Phase 3 randomized controlled trials. Two investigators independently screened records (using Rayyan), extracted data and assessed risk of bias with RoB 2; certainty was rated with GRADE. Outcomes were pooled as risk ratios (RR) or mean differences with 95% confidence intervals (CI) using RevMan 5.4. RESULTS: Three trials (EAGLE-2, EAGLE-3 and EAGLE-J) including 3510 participants (gepotidacin n = 1853; nitrofurantoin n = 1657) were included. Gepotidacin increased composite therapeutic success versus nitrofurantoin (RR 1.20; 95% CI 1.10-1.31; I2 = 0%; P < 0.001) and improved microbiological eradication (RR 1.14; 95% CI 1.07-1.21; I2 = 2%; P < 0.001). Gastrointestinal adverse events were more frequent with gepotidacin (diarrhoea RR 5.51; 95% CI 4.08-7.45; nausea RR 2.49; 95% CI 1.56-3.97). Serious adverse events were rare and similar between groups. Certainty of evidence per outcome is presented in Table S2 (available as Supplementary data at JAC Online). CONCLUSIONS: Gepotidacin provides superior composite and microbiological outcomes relative to nitrofurantoin for female uUTI but is associated with increased mild-to-moderate gastrointestinal toxicity. Long-term tolerability and resistance surveillance are recommended.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。